HEALTHCARE INSIGHTS https://validator.w3.org/feed/docs/rss2.html Vol 51_Nov.09.2026_Newsletter VIETNAM TARGETS AT LEAST 20% FEWER HOSPITAL REFERRALS THROUGH TECHNICAL TRANSFER REFORM: CAN OUTCOME-BASED CAPACITY BUILDING REDUCE PRESSURE ON TERTIARY HOSPITALS? Bubble tea, birthday cake and business dinners: The hidden calorie traps of office life Choking: Back Blows Or Abdominal Thrusts? Getting The First Few Minutes Right Beyond reviewing AI output: Rebuilding the organization around new decisions US employee engagement hits a 15-year low: eight perspectives for managers and lessons for healthcare US RISKS LOSING MEASLES ELIMINATION STATUS AFTER MORE THAN 5,100 CASES IN 2026: WHY MAINTAINING THE CURRENT RESPONSE MAY NOT BE ENOUGH TO RESTORE COMMUNITY IMMUNITY CHINA’S DRUGMAKERS TURN TO AI PLATFORMS TO REACH DOCTORS: COULD MEDICAL AI DISRUPT THE TRADITIONAL PHARMACEUTICAL SALES MODEL? ASPEN WINS GENERIC SEMAGLUTIDE APPROVALS IN BRAZIL AND SOUTH AFRICA: CAN LOWER-COST GLP-1 COMPETITION CHALLENGE NOVO NORDISK’S MARKET ADVANTAGE? PFIZER SECURES UP TO $1.5 BILLION FROM BLACKSTONE FOR OBESITY DRUG DEVELOPMENT: WHY R&D RISK-SHARING COULD BECOME A NEW COMPETITIVE ADVANTAGE IN GLP-1 PHU QUOC PLANS VND 1.3 TRILLION, 500-BED HOSPITAL: WHY INFRASTRUCTURE EXPANSION ALONE CANNOT SOLVE THE ISLAND’S HEALTHCARE CAPACITY CHALLENGE BEAM’S RISTO-CEL MEETS PIVOTAL SICKLE CELL TRIAL ENDPOINT: CAN BASE EDITING CHALLENGE CASGEVY AND LYFGENIA IN THE GENE THERAPY MARKET? BAYER WINS FDA APPROVAL FOR SUNHARBO WITH 26% LOWER RECURRENT STROKE RISK: CAN FIRST-IN-CLASS FACTOR XIa INHIBITION DRIVE GROWTH BEYOND XARELTO? DAVITA AND FRESENIUS FACE WASHINGTON ANTITRUST LAWSUIT: WHY MEDICAL DIRECTOR RESTRICTIONS COULD BECOME A STRATEGIC RISK FOR DIALYSIS CHAINS ASTRAZENECA ACQUIRES OMNIOSE TO STRENGTHEN BACTERIAL VACCINE DEVELOPMENT: WHY MANUFACTURING TECHNOLOGY COULD BECOME A STRATEGIC ADVANTAGE AGAINST ANTIMICROBIAL RESISTANCE FDA WARNS OF RARE VISION LOSS RISK WITH GLP-1 DRUGS: WHY SAFETY COMMUNICATION COULD BECOME CRITICAL TO PATIENT TRUST AND TREATMENT CONTINUITY S.I.S CAN THO HOSPITAL RECEIVES NEW ENVIRONMENTAL PERMIT AFTER VND 2.09 BILLION FINE: WHY OPERATIONAL COMPLIANCE IS BECOMING A STRATEGIC RISK FOR PRIVATE HOSPITALS IMEXPHARM ATTRACTS BULLISH 2027 EXPECTATIONS: WHY 5% PROFIT GROWTH HAS NOT YET SOLVED ITS PHARMACEUTICAL REVENUE CHALLENGE DUC GIANG HOSPITAL LINKS WITH PRIMARY CARE TO MANAGE CHRONIC DISEASES: WHY CONTINUOUS CARE COULD BECOME THE KEY TO REDUCING HOSPITAL OVERLOAD TAM ANH HOSPITAL SECURES EXCLUSIVE JAPANESE CELL TECHNOLOGY TRANSFER: WHY TECHNOLOGICAL OWNERSHIP IS NOT YET PROOF OF A CANCER TREATMENT BREAKTHROUGH 686 HANOI HEALTHCARE FACILITIES LINKED TO $340,000 LICENSING SCANDAL: WHY REGULATORY FAILURES THREATEN TRUST IN VIETNAM’S PRIVATE HEALTHCARE MARKET ARGENX STRIKES $1.15 BILLION DEAL FOR UNNATURAL PRODUCTS: WHY ORAL PEPTIDES COULD BECOME THE NEXT GROWTH PLATFORM IN IMMUNOLOGY J&J WINS ACCELERATED FDA APPROVAL FOR RYBREVANT FASPRO IN HEAD AND NECK CANCER: WHY A 42% RESPONSE RATE IS NOT YET PROOF OF A SURVIVAL ADVANTAGE FDA ORDERS NEW VISION-LOSS WARNINGS FOR GLP-1 DRUGS: WHY LONG-TERM SAFETY IS BECOMING A NEW COMPETITIVE FACTOR IN OBESITY TREATMENT CVC’S PHUONG CHAU HOSPITAL EXIT STALLS: WHY STRONG GROWTH IS NOT ENOUGH TO SECURE A PREMIUM HEALTHCARE M&A VALUATION MODERNA RAISES 2026 OUTLOOK ON INTERNATIONAL COVID VACCINE DEMAND: WHY STRONGER EARNINGS DO NOT YET SOLVE ITS POST-PANDEMIC GROWTH CHALLENGE NOVARTIS REPORTS TWO TUMOUR CASES LINKED TO ZOLGENSMA: WHY LONG-TERM CANCER RISK IS BECOMING A CRITICAL TEST FOR GENE THERAPY VIETNAM SEEKS GREATER TRANSPARENCY IN DRUG AND MEDICAL DEVICE PRICING: WHY PRICE DISCLOSURE ALONE CANNOT FIX HOSPITAL PROCUREMENT CA MAU GENERAL HOSPITAL EARNS DIAMOND STROKE CARE RECOGNITION: WHY STANDARDIZED EMERGENCY SYSTEMS MAY MATTER MORE THAN HOSPITAL CAPACITY EXPANSION VIETNAM PROPOSES TIGHTER RULES FOR FOOD SUPPLEMENTS: WHY SCIENTIFIC EVIDENCE COULD BECOME THE NEXT COMPETITIVE ADVANTAGE HA THANH OPENS NEW HOSPITAL IN HO CHI MINH CITY: WHY PRIVATE HEALTHCARE EXPANSION IS ABOUT MORE THAN BUILDING MODERN FACILITIES VIETNAM INTRODUCES DEDICATED GMP STANDARDS FOR INVESTIGATIONAL DRUGS FROM 2027: WHY REGULATORY SPECIALIZATION COULD RESHAPE PHARMACEUTICAL R&D Are you overweight without knowing it? Understanding BMI, waist circumference and visceral fat Nosebleeds: Head Back Or Head Forward? Correcting A Common First Aid Mistake When the workload outgrows the team: How leaders can rebalance the load The hidden cost of losing in-house capability through outsourcing: lessons for healthcare organizations LONG CHAU REACHES 36 MILLION CUSTOMERS: WHY VIETNAM’S PHARMACY MARKET IS SHIFTING TOWARD INTEGRATED COMMUNITY HEALTHCARE GERMANY SEEKS MORE VIETNAMESE NURSES: WHY INTERNATIONAL HEALTHCARE RECRUITMENT IS BECOMING A RETENTION CHALLENGE FOR VIETNAM MERCK–MODERNA’S PERSONALIZED CANCER VACCINE CUTS MELANOMA RECURRENCE RISK BY 42%: WHY THE NEXT ONCOLOGY BATTLE MAY BE FOUGHT OVER INDIVIDUALIZED DRUG MANUFACTURING HCMC RECALLS SUBSTANDARD PIRACETAM 400MG BATCH: WHY PHARMACEUTICAL QUALITY CONTROL IS BECOMING A STRATEGIC BUSINESS PRIORITY IN VIETNAM MEDLATEC–TNH STRATEGIC PARTNERSHIP: WHY VIETNAM’S NEXT HEALTHCARE GROWTH MODEL MAY DEPEND ON CONNECTED HOSPITAL AND DIAGNOSTIC NETWORKS LONG CHAU-LED WOMEN’S CANCER ALLIANCE: WHY VIETNAM’S NEXT HEALTHCARE OPPORTUNITY LIES IN CONNECTING SCREENING WITH CONTINUOUS CANCER CARE VIETNAM TARGETS NEXT-GENERATION VACCINE MANUFACTURING BY 2028: WHY TECHNOLOGY TRANSFER COULD REDEFINE THE COUNTRY’S PHARMACEUTICAL INDUSTRIAL STRATEGY BACH MAI HOSPITAL APPOINTS NEW DEPUTY DIRECTOR: WHY CLINICAL LEADERSHIP COULD BECOME A DECISIVE FACTOR IN VIETNAM’S HOSPITAL MODERNIZATION VIETNAM’S HOSPITAL 108 EXPLORES RDIF BIOTECH COOPERATION: WHY CLINICAL VALIDATION, NOT FOREIGN CAPITAL, WILL DEFINE THE REAL OPPORTUNITY VIETNAM’S HEALTHCARE AI MARKET ENTERS A NEW PHASE: WHY CLINICAL VALUE, NOT ALGORITHMIC POWER, WILL DETERMINE THE WINNERS IMEXPHARM AFTER LIVZON’S TAKEOVER: STRONGER MARGINS, WEAKER SALES – THE REAL TEST OF VIETNAM’S NEXT PHARMA GROWTH STORY VIETNAM’S NEAR-VND 2 TRILLION PROTON THERAPY INVESTMENT: A BREAKTHROUGH IN CANCER CARE OR A TEST OF HEALTHCARE CAPITAL EFFICIENCY? BAYER’S ASUNDEXIAN WINS FIRST GLOBAL APPROVAL IN CHINA: CAN FACTOR XIA INHIBITION RESHAPE THE STROKE PREVENTION MARKET? Recent Activity